Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Otsuka Pharmaceutical has submitted a manufacturing and marketing approval application for the dopamine agonist transdermal patch, Rotigotine Patch, in Japan.
Subscribe to our email newsletter
Rotigotine Patch has been developed as a treatment for Parkinson’s disease and restless legs syndrome.
The patch will provide a continuous release of the drug substance and maintains a clinically effective blood drug concentration for 24 hours to achieve stable effects.
Rotigotine Patch was developed to lessen the symptoms that can occur during the day or night and to provide patients with a convenient form of drug treatment, the company said.